Subject:
All Disciplines Arts & Humanities Biology & Life Sciences Business & Economics Chemistry & Materials Science Computer Science & Mathematics Engineering Environmental & Earth Sciences Medicine & Pharmacology Physical Sciences Public Health & Healthcare Social Sciences
Sort:
Hottest Latest Alphabetical (A-Z) Alphabetical (Z-A)
Type:
All Topic Review Biography
Topic Review
Venous Thromboembolisms (VTEs) in Total Knee Arthroplasty (TKA)
The entry provides a comprehensive overview of Venous Thromboembolisms (VTEs) in Total Knee Arthroplasty (TKA), a significant orthopedic procedure. It begins by highlighting the persistent threat of VTEs despite improvements in surgical techniques and preventive measures. The prevalence and incidence of VTEs are discussed, showcasing a notable decrease over the years. The clinical significance of VTEs, including their impact on patient outcomes and healthcare costs, is emphasized, underscoring the need for effective management strategies. Various risk factors contributing to VTE development post-TKA are explored, including demographic factors, cardiopulmonary status, preoperative mobilization status, and malignancy. The section on prevention outlines existing guidelines and challenges, with a focus on the efficacy and safety of aspirin as a prophylactic agent. Finally, the conclusion emphasizes the importance of a comprehensive approach to address VTEs in TKA, encompassing evidence-based guidelines, personalized patient care, and strategies to enhance adherence to preventive measures.
  • 218
  • 30 Apr 2024
Topic Review
Venous Thromboembolism Risk Assessment in Ambulatory Cancer Patients
Cancer patients are at greater risk of developing venous thromboembolism compared to the general population, which can lead to a decreased quality of life, a worsened prognosis, and increased treatment costs. Many cancer patients will experience venous thromboembolism (VTE) at some stage, with the highest rate in the initial period following diagnosis. Novel cancer therapies may further enhance the risk. VTE in a cancer setting is associated with poor prognostic, a decreased quality of life, and high healthcare costs.
  • 151
  • 31 Jan 2024
Topic Review
Venous Thromboembolism Prevention in Multiple Myeloma
Multiple myeloma (MM) is associated with an increased risk of thrombotic complications, which remains substantial despite the implementation of thromboprophylaxis. The procoagulant state that characterizes the disease is multifactorial, and a greater understanding of the underlying pathophysiology is required to inform appropriate thrombosis prevention. There is a shift towards using direct oral anticoagulants (DOACs) in this setting; head-to-head comparisons in the context of controlled clinical trials between class agents are still missing. MM-specific venous thromboembolism (VTE) risk assessment scores have been developed to optimize management and minimize the associated mortality/morbidity. Their clinical utility remains to be evaluated. 
  • 520
  • 29 Dec 2022
Topic Review
Venom Insulin Derived from Cone Snails
Cone snails possess a diverse array of novel peptide toxins, which selectively target ion channels and receptors in the nervous and cardiovascular systems. These numerous novel peptide toxins are a valuable resource for future marine drug development. 
  • 94
  • 22 Jan 2024
Topic Review
Veno-Arterial Extracorporeal Membrane Oxygenation
Mortality in infarct-related cardiogenic shock (CS) remains high, reaching 40–50%. In refractory CS, active mechanical circulatory support devices including veno-arterial extracorporeal membrane oxygenation (VA-ECMO) are rapidly evolving. However, supporting evidence of VAECMO therapy in infarct-related CS is low. The basics of VA-ECMO therapy, current evidence, ongoing trials, patient selection and potential complications warrant focus.
  • 357
  • 12 Apr 2022
Topic Review
Venetoclax in the Treatment of Younger AML Patients
The combination approach based on venetoclax (VEN) with azacytidine (AZA) has significantly improved outcomes for elderly patients with acute myeloid leukemia (AML). This innovative approach has led to higher rates of overall response, measurable residual disease (MRD)-negative remissions, and overall survival compared with AZA monotherapy. As a result, this combination has emerged as the gold-standard treatment for elderly or unfit patients with AML who are not eligible for intensive therapy. In younger, fit patients with AML, intensive induction and consolidation chemotherapy is commonly used as a first-line approach; however, relapse continues to be the main reason for treatment failure in approximately 30–40% of patients. Efforts to improve MRD-negative response rates and to facilitate the transition to allogeneic hematopoietic stem cell transplantation, particularly in high-risk AML, have inspired trials exploring the combination of intensive chemotherapy with targeted agents. VEN, a first-in-class anti-BCL2 agent, combined with intensive chemotherapy regimens has shown deep MRD-negative remissions, producing prolonged event-free survival and enhancing the transition to allogeneic transplant in first-complete-remission patients. These benefits support the incremental advantages of adding VEN to intensive chemotherapy approaches across ELN risk subcategories, and provides a robust benchmark to design future trials.
  • 136
  • 09 Jan 2024
Topic Review
Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia
Relapsed and/or refractory (R/R) acute myeloid leukemia (AML) represents one of the most challenging scenarios in hematology, with a 5-year survival of only 10%. Venetoclax is a small molecule that acts as a potent, selective inhibitor of BCL-2. Given its satisfactory safety profile, VEN-based combinations are increasingly being investigated as a part of the therapeutic strategy for R/R AML. On the other hand, the issue of overcoming resistance is one of the most important fields to be addressed in upcoming clinical research.
  • 483
  • 22 May 2023
Topic Review
Venetoclax Combination Therapies in Pediatric Hematological Malignancies
Venetoclax is a strongly effective B-cell lymphoma-2 inhibitor (BCL-2) with an ability to selectively restore the apoptotic potential of cancerous cells. It has been proven that in combination with immunotherapy, targeted therapies, and lower-intensity therapies such as hypomethylating agents (HMAs) or low-dose cytarabine (LDAC), the drug can improve overall outcomes for adult patients with acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM), amongst other hematological malignancies.
  • 153
  • 07 Feb 2024
Topic Review
Venetoclax and Hypomethylating Agent Combination in Myeloid Malignancies
There has been a widespread adoption of hypomethylating agents (HMA: 5-Azacytidine (5-Aza)/decitabine) and venetoclax (Ven) for the treatment of acute myeloid leukemia (AML); however, the mechanisms behind the combination’s synergy are poorly understood. Monotherapy often encounters resistance, leading to suboptimal outcomes; however, the combination of HMA and Ven has demonstrated substantial improvements in treatment responses.
  • 198
  • 26 Feb 2024
Topic Review
Velopharyngeal Insufficiency Treatment in Cleft Palate Patients
Cleft lip and palate (CLP) are one of the most common congenital anomalies with a global prevalence of 1:700. Velopharyngeal insufficiency may occur as a result of an anatomical or structural defect and may be present in patients with cleft lip and palate. The treatment options presented in the literature are varied, covering invasive and non-invasive methods.
  • 368
  • 09 Sep 2022
  • Page
  • of
  • 1352
Featured Entry Collections
>>

Featured Books

>>
Encyclopedia of Social Sciences
Encyclopedia of COVID-19
Encyclopedia of Fungi
Encyclopedia of Digital Society, Industry 5.0 and Smart City
Video Production Service
Feedback